Phase 1 trial of vorolanib plus everolimus for advanced kidney cancer

A new combination of vorolanib, a tyrosine kinase inhibitor plus everolimus, an mTOR inhibitor shows promise for the treatment of advanced renal cell carcinoma (RCC). A phase 1 study looking at how well the combination is tolerated by patients, safety (side effects), and how the combination works in the body, has shown some promise. Twenty-two […]

read more
Showing the single result
  TOP